Healthcare Sales & Marketing Network News: white blood cells

Searching News Database: white blood cells

HSMN NewsFeed - 27 Feb 2026
Norgine Welcomes Positive CHMP Opinion Recommending Approval of Mavorixafor in the European Union for WHIM Syndrome
Biopharmaceuticals Regulatory

HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 May 2023
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Apr 2023
Soligenix Provides Regulatory Update on HyBryte(TM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Feb 2023
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Aug 2022
Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Jun 2022
Scopio Labs Awarded FDA Clearance for High Throughput Hematology Digital Cell Morphology Platform, Replacing Microscopes with Digitization
Devices Diagnostics FDA

HSMN NewsFeed - 18 Mar 2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease
Biopharmaceuticals

HSMN NewsFeed - 15 Dec 2021
FDA Approves First Drug to Prevent Graft Versus Host Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Oct 2021
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Apr 2020
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA

HSMN NewsFeed - 30 Jul 2019
Lilly's Verzenio(R) (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Jun 2019
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Apr 2019
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Mar 2019
Novartis receives FDA approval for Mayzent(R) (siponimod), the first oral drug to treat secondary progressive MS with active disease
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 7 Jan 2019
Lilly Announces Agreement To Acquire Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 18 Dec 2018
Lilly Announces Publication of Analyses Showing Benefit of the Addition of Verzenio(R) (Abemaciclib) in Multiple Subgroups of Patients with Advanced Breast Cancer Identified as Having a More Concerning Prognosis
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Dec 2018
PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi(TM) (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
Biopharmaceuticals Regulatory

HSMN NewsFeed - 5 Nov 2018
EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 1 Nov 2018
AbbVie Receives European Commission Approval of VENCLYXTO(R) (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Oct 2018
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Aug 2018
Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Aug 2018
Siklos(R), the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now available in retail pharmacies
Biopharmaceuticals Product Launch

HSMN NewsFeed - 20 Aug 2018
Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Aug 2018
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Jun 2018
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Jun 2018
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine(R) (sargramostim) for the Treatment of Acute Radiation Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
Biopharmaceuticals FDA

HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 May 2018
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Mar 2018
Q Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing Facility for Non-Opioid Strontium Chloride SR89 Injection USP for Relief of Cancer Bone Pain
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Mar 2018
Roche launches the new cobas m 511 analyzer, signaling a new era in hematology testing
Diagnostics FDA Product Launch

HSMN NewsFeed - 27 Feb 2018
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
Biopharmaceuticals Drug Delivery Regulatory

HSMN NewsFeed - 1 Feb 2018
Partner Therapeutics (PTx) Acquires Leukine(R) from Sanofi
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 17 Jan 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Jan 2018
Novartis drug Promacta(R) receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 1 Dec 2017
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Nov 2017
Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate(R) (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
Biopharmaceuticals Regulatory

HSMN NewsFeed - 12 Oct 2017
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio(TM) (abemaciclib) as Initial Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 1 Sep 2017
FDA approves Mylotarg for treatment of acute myeloid leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Aug 2017
Abbott Introduces HeartMate 3 Left Ventricular Assist System - the Latest Milestone In Therapy For Advanced Heart Failure Patients
Devices Cardiology FDA Product Launch

HSMN NewsFeed - 24 Jul 2017
eFFECTOR Therapeutics Completes $38.6 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Apr 2017
Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
Biopharmaceuticals Regenerative Medicine Oncology

HSMN NewsFeed - 24 Mar 2017
FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA Product Launch

HSMN NewsFeed - 22 Mar 2017
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Jan 2017
FDA Grants Priority Review for Genentech’s Actemra(R) (Tocilizumab) Supplemental Biologics License Application for Giant Cell Arteritis, a Form of Vasculitis
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Oct 2016
Teva Receives Positive Opinion from European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to Extend Indication of Trisenox(R) for First Line Treatment of Low- to Intermediate Risk Acute Promyelocytic Leukemia (APL)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Sep 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Jun 2016
ARIAD Announces Distribution Agreements for Iclusig(R) in Latin America and the Middle East/North Africa
Biopharmaceuticals Distribution

HSMN NewsFeed - 11 May 2016
Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
Biopharmaceuticals Regenerative Medicine

HSMN NewsFeed - 9 May 2016
U.S. FDA Expands IMBRUVICA(R) (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Apr 2016
Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 4 Feb 2016
Phase 3 Study of BLINCYTO(R) (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Dec 2015
Kesios Therapeutics Raises £19 Million in Series A Financing
Biopharmaceuticals Oncology Personnel Venture Capital

HSMN NewsFeed - 26 Oct 2015
Michael Bruch Appointed Chief Financial Officer of Cesca Therapeutics
Regenerative Medicine Personnel

HSMN NewsFeed - 11 Aug 2015
Rich Pharmaceuticals, Inc. Appoints Richard Salvador, Ph.D., Research & Development Expert, To Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 4 Feb 2015
Genentech’s Phase III Study of Gazyva(R) Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jan 2015
NovaBay Expands Sales Force for Avenova
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 6 Oct 2014
Mylan Launches Generic Combivir
Biopharmaceuticals Generics HIV/AIDS Product Launch

HSMN NewsFeed - 8 Sep 2014
Successful Completion of Phase III Program for Teva’s Reslizumab Two More Phase Iii Studies Support the Benefits of Reslizumab Treatment in Asthma Patients with Eosinophilia
Biopharmaceuticals

HSMN NewsFeed - 27 Aug 2014
Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta(R)/Revolade(TM) For Use in Patients with Severe Aplastic Anemia
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Jul 2014
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA(R) (ibrutinib) for Treatment of Two Blood Cancers
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Apr 2014
Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 13 Mar 2014
Umbra Applied Technologies Group Introduces New Blood Management System Powered by Cellgevity(TM)
Devices Product Launch

HSMN NewsFeed - 7 Mar 2014
Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera
Biopharmaceuticals

HSMN NewsFeed - 15 Jan 2014
Antares Pharma Announces Availability of OTREXUP (Methotrexate) Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis (pJIA) in Children
Biopharmaceuticals Drug Delivery Product Launch

HSMN NewsFeed - 2 Jan 2014
Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Dec 2013
FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 18 Nov 2013
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
Biopharmaceuticals

HSMN NewsFeed - 1 Nov 2013
FDA Approves Gazyva (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Oct 2013
ARIAD Announces Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Aug 2013
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Jul 2013
Sequenta Completes $20 Million Series C Financing
Diagnostics Oncology Venture Capital Personnel

HSMN NewsFeed - 2 Jul 2013
ARIAD Announces Marketing Authorization for Iclusig(R) (ponatinib) in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Jul 2013
FDA Grants Genentech’s Perjeta Regimen Priority Review for Use Before Surgery in HER2-Positive Early Stage Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 Jun 2013
Teva’s Lonquex(R)(XM22 lipegfilgrastim) Recommended for Approval in the EU for the Reduction of Chemotherapy-Induced Neutropenia (CIN)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA

HSMN NewsFeed - 8 Apr 2013
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Mar 2013
NovaBay Names Keith Bley as Senior Vice President of Product Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Feb 2013
Valeant Pharmaceuticals Acquires U.S. Rights to Targretin(R) from Eisai Inc.
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 26 Oct 2012
Teva Receives Approval For SYNRIBO(TM) (Omacetaxine Mepesuccinate) for Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Oct 2012
Clinical Study Validates Sequenta’s LymphoSIGHT(TM) Platform as More Sensitive Alternative to Flow Cytometry for Cancer Detection
Diagnostics Oncology

HSMN NewsFeed - 4 Oct 2012
Sigma-Tau Pharmaceuticals, Inc. Receives FDA Approval of CYSTARAN(TM) (Cysteamine Ophthalmic Solution) 0.44% for Treatment of Corneal Cystine Crystals in Cystinosis Patients
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 13 Sep 2012
NovaBay's NeutroPhase(R) Used in New Therapeutic Technique for Management of Necrotizing Fasciitis
Biopharmaceuticals Wound Care

HSMN NewsFeed - 30 Aug 2012
Teva Announces FDA Grants Approval for Tbo-filgrastim for the Treatment of Chemotherapy-Induced Neutropenia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Aug 2012
Life of Cancer Patient Suffering From Bone Marrow Failure Saved Following Treatment With Pluristem's PLX Cells
Regenerative Medicine Oncology

HSMN NewsFeed - 22 Jun 2012
New Data From Phase III Study Showed That People With HER2-Positive Metastatic Breast Cancer Lived Longer With Genentech’s Perjeta
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 May 2012
Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn’s Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance Phases
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 6 Dec 2011
Amgen and FDA Agree to Modify Nplate(R) (Romiplostim) Risk Evaluation and Mitigation Strategy
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Oct 2011
ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Oct 2011
Abbott's Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA
Diagnostics FDA

HSMN NewsFeed - 14 Oct 2011
NovaBay Pharmaceuticals Spotlights NeutroPhase(R) at the Symposium on Advanced Wound Care (SAWC)
Biopharmaceuticals Wound Care

HSMN NewsFeed - 14 Sep 2011
ApoPharma Announces FDA Advisory Committee Recommendation in Favor of Ferriprox(R) (deferiprone) Approval
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Apr 2011
Novartis Therapy Gilenya Reduced the Risk of MS Disability Progression Regardless of Treatment History or Disease Severity, New Analysis Shows
Biopharmaceuticals Neurology

HSMN NewsFeed - 24 Feb 2011
FDA Grants Genentech a Hearing on Avastin’s Use for Metastatic Breast Cancer in the United States
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Feb 2011
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Dec 2010
Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Dec 2010
Sequenta, Inc. Secures $13 Million in Series B Financing
Diagnostics Venture Capital

HSMN NewsFeed - 15 Nov 2010
FDA Approves Eisai’s Halaven(TM) (Eribulin Mesylate) Injection for Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Nov 2010
Semafore Pharmaceuticals Receives FDA Orphan Drug Designation for SF1126 in the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Oct 2010
NovaBay Pharmaceuticals Appoints Gail Maderis, BayBio President and CEO and Former Genzyme Senior Executive, to Its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Sep 2010
Novartis gains FDA approval for Gilenya, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 24 Aug 2010
Baxter Announces Manufacturing, Supply and Distribution Agreement with Kamada for GLASSIA
Biopharmaceuticals Distribution

HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Jan 2010
Two-Year Results From CLARITY Study with Cladribine Tablets in Multiple Sclerosis Published in The New England Journal of Medicine
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 Jan 2010
Novartis Launches Schizophrenia Treatment Fanapt in the US, Offering Patients an Attractive Alternative to Existing Medications
Biopharmaceuticals

HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Dec 2009
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Nov 2009
Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Oct 2009
NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Oct 2009
Ortho Clinical Diagnostics Receives FDA Approval for First Anti-HIV 1+2 Test for Use on Random Access, Integrated Laboratory Testing System
Diagnostics FDA HIV/AIDS

HSMN NewsFeed - 8 Oct 2009
FDA Advisory Committee Recommends Approval of Pfizer's Selzentry for Use in Patients Starting HIV Therapy for the First Time
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 3 Aug 2009
NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Jul 2009
Regeneron Receives European Medicines Agency Positive Opinion for Marketing Authorization of Rilonacept for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 10 Jul 2009
ALIMTA(R) (pemetrexed for injection) First Agent Approved in Europe as Maintenance Therapy for Advanced, Nonsquamous Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 6 Jul 2009
Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 May 2009
ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer
Biopharmaceuticasl Oncology Regulatory

HSMN NewsFeed - 11 May 2009
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 25 Mar 2009
NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions
Biopharmaceuticals Dermatology

HSMN NewsFeed - 23 Mar 2009
U.S. FDA Approves New THERAKOS(TM) CELLEX(TM) Photopheresis System
Devices Oncology FDA

HSMN NewsFeed - 16 Mar 2009
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 23 Feb 2009
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC Joint Venture upon CTI's Fulfillment of Closing Conditions
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 13 Feb 2009
ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
Biopharmaceuticals

HSMN NewsFeed - 11 Feb 2009
Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument
Diagnostics FDA

HSMN NewsFeed - 9 Feb 2009
ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
Biopharmaceuticals

HSMN NewsFeed - 30 Jan 2009
REVLIMID Receives Preliminary Positive Recommendation from National Institute for Health and Clinical Excellence (NICE) for Use in the National Health Service (NHS) in England and Wales
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Jan 2009
Merck Serono's Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial
Biopharmaceuticals Neurology

HSMN NewsFeed - 22 Jan 2009
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jan 2009
NovaBay (NBY) Appoints Harry F. Hixson, Jr., PhD, Former Amgen President/Chief Operating Officer to Its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Dec 2008
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2008
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Dec 2008
Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma
Devices Wound Care

HSMN NewsFeed - 1 Dec 2008
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Nov 2008
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Oct 2008
High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Oct 2008
Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization from Health Canada for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 29 Sep 2008
FDA Grants Lilly's ALIMTA(R) (Pemetrexed for Injection) Third U.S. Approval
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Aug 2008
FDA Approves Nplate(TM) for Long-Term Treatment of Adult Chronic ITP
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Aug 2008
Cerus' INTERCEPT Blood System Receives CE Mark Label Expansion for Treatment of Previously Frozen Plasma
Devices Regulatory

HSMN NewsFeed - 5 Aug 2008
Panacea Pharmaceuticals Announces Appointment of Suzanne Sensabaugh as Vice President, Regulatory Affairs
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Aug 2008
Craig W. Philips Takes Helm at CTI
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jul 2008
Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug, Polyphenon E, for the Treatment of CLL
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Jul 2008
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Jun 2008
Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP)
Devices Cardiology Regenerative Medicine

HSMN NewsFeed - 18 Jun 2008
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Jun 2008
Medicis to Acquire LipoSonix
Devices Mergers & Acquisitions

HSMN NewsFeed - 1 Jun 2008
Updated REVLIMID(R) Data Presented in Newly Diagnosed Multiple Myeloma Presented at the 2008 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 May 2008
ADVEXIN(R) Improves Survival in Recurrent, Refractory Head and Neck Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 May 2008
New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Apr 2008
Thalidomide Pharmion(TM) Granted Full Marketing Authorization for Treatment of Newly Diagnosed Multiple Myeloma in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 15 Apr 2008
Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
Devices Cardiology

HSMN NewsFeed - 7 Apr 2008
Thalidomide Pharmion(R) Receives Marketing Approval from Australian Therapeutic Goods Administration for Treatment of Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 25 Mar 2008
ARCALYST(TM) (rilonacept), First and Only FDA-approved Treatment for Cryopyrin-Associated Periodic Syndromes (CAPS), Now Available in the United States
Biopharmaceuticals

HSMN NewsFeed - 7 Mar 2008
In Post-Vioxx Era, Biologics Are Reviving Arthritis Treatment Market
Biopharmaceuticals

HSMN NewsFeed - 27 Feb 2008
FDA Approves Regeneron's ARCALYST(TM) (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Feb 2008
Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Feb 2008
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Feb 2008
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Feb 2008
Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 11 Feb 2008
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Feb 2008
MethylGene and Pharmion Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Feb 2008
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
Biopharmaceuticals

HSMN NewsFeed - 31 Jan 2008
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Jan 2008
Celgene Reports on REVLIMID(R) (Lenalidomide) Global Regulatory Developments in Multiple Myeloma and Deletion 5Q Myelodysplastic Syndromes
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Jan 2008
Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Jan 2008
NovaBay Pharmaceutical's Investigational New Drug Application (IND) for the Prevention of Catheter Associated Urinary Tract Infections Cleared by FDA
Biopharmacuticals

HSMN NewsFeed - 27 Dec 2007
Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 9 Dec 2007
SWOG Phase III Trial Reports REVLIMID(R) (lenalidomide) Plus Dexamethasone Achieves Superior Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2007
REVLIMID(R) (Lenalidomide) Plus Low-Dose Dexamethasone Achieves Unprecedented Survival Rate in ECOG Phase III Trial in Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Nov 2007
Tasigna(R) gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 12 Nov 2007
Cancer Drug REVLIMID(R) Receives Recommendation for Approval from Australian Drug Evaluation Committee for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 1 Nov 2007
Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
Diagnostics FDA

HSMN NewsFeed - 29 Oct 2007
Tasigna(R) receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Oct 2007
Celera Completes Acquisition of Atria Genetics, Inc.
Diagnostics Acquisitions

HSMN NewsFeed - 22 Oct 2007
Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Sep 2007
Pfizer's Celsentri(R) Approved in the European Union, Providing a Novel Treatment Option for Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 20 Sep 2007
CG Therapeutics Appoints Dr. Christopher S. Henney as Chairman of Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Sep 2007
Celera to Acquire Atria Genetics
Diagnostics Acquisitions

HSMN NewsFeed - 18 Sep 2007
New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
Biopharmaceuticals

HSMN NewsFeed - 10 Sep 2007
INNOVIVE Pharmaceuticals Acquires Exclusive Rights to Develop and Commercialize Tamibarotene in Europe
Biopharmaceuticals Licensing Oncology

HSMN NewsFeed - 4 Sep 2007
Oral Cancer Drug REVLIMID(R) Receives Swissmedic Approval in Switzerland for Treatment of Multiple Myeloma
Biopharmaceuticals Regulatory Oncology

HSMN NewsFeed - 16 Aug 2007
Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions Oncology

HSMN NewsFeed - 14 Aug 2007
Misonix Highlights Recent Duke University Study Revealing Significant New Cancer Treatment May Be Possible with HIFU Technology
Devices Oncology

HSMN NewsFeed - 6 Aug 2007
Pfizer's SelzentryTM (Maraviroc) Tablets, Novel Treatment for HIV, Approved by FDA
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 25 Jul 2007
Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48 Week Data Show
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 19 Jul 2007
Abraxis BioScience and Biocon Limited Announce Licensing Agreement for G-CSF in North America and the European Union
Biopharmaceuticals Licensing

HSMN NewsFeed - 17 Jul 2007
Panacea Pharmaceuticals Announces the Availability of LC Detect(sm), a Serum-Based Diagnostic Test for Lung Cancer
Diagnostics Oncology

HSMN NewsFeed - 26 Jun 2007
Cerus Announces Agreement to Supply the INTERCEPT Blood System for Platelets to French National Blood Service
Devices

HSMN NewsFeed - 19 Jun 2007
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 15 Jun 2007
KCI Enters into Exclusive Worldwide License with NovaBay for NeutroPhase(TM) Wound Treatment Solution Technology
Devices Biopharmaceuticals Wound Care Licensing

HSMN NewsFeed - 7 Jun 2007
INNOVIVE Pharmaceuticals Receives FDA Fast Track Designation for Tamibarotene for the Treatment of Acute Promyelocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Jun 2007
8-Year Long-Term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission With Bexxar(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Pharmion Announces French ATU Granted for Use of Thalidomide for Elderly Patients With Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 3 Jun 2007
FOLFOX4 (Eloxatin(R)-based Chemotherapy) After Surgery Improves Overall Survival in Patients With Early (Stage III) Colon Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Study Supports Activity of GEMZAR(R) (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2007
Panacea Pharmaceuticals Announces the Availability of PC Detect(sm) for Prostate Cancer Screening
Diagnostics Oncology

HSMN NewsFeed - 15 May 2007
SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232) Closed and Patients Given Choice to Switch to REVLIMID(R) Plus Dexamethasone
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Apr 2007
FDA Advisory Committee Recommends Accelerated Approval of Pfizer's Maraviroc for Treatment-Experienced Patients Infected with CCR5-tropic HIV-1
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 17 Apr 2007
Pro-Pharmaceuticals Issues Corporate Update
Biopharmaceuticals

HSMN NewsFeed - 4 Apr 2007
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Apr 2007
The Immune Response Corporation Announces Rebranding to Reflect Expanded Focus on Treatment of Autoimmune Diseases
Biopharmaceuticals

HSMN NewsFeed - 23 Mar 2007
Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for Treatment of Multiple Myeloma From European Medicines Agency
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 Mar 2007
The Immune Response Corporation Injects First Patient in Trial of NeuroVax(TM) for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 1 Mar 2007
Pfizer's Maraviroc, Novel Medicine For HIV, Significantly Reduces Viral Load, in Combination Therapy Across Range of Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 1 Mar 2007
EMEA Accepts for Review Thalidomide Pharmion(R) Marketing Authorization Application for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 1 Mar 2007
European Committee Issued Positive Opinions to Extend Indication for PREVENAR to Include Pneumonia and Otitis Media
Biopharmaceuticals Regulatory

HSMN NewsFeed - 1 Mar 2007
Haemonetics(R) Launches Next Generation Mobile Blood Donation System
Devices FDA

HSMN NewsFeed - 13 Feb 2007
Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 8 Feb 2007
SRI International and Telik Announce Exclusive License for SRI to Develop Autoimmune and Inflammatory Disease Drug Candidate
Biopharmaceuticals Licensing

HSMN NewsFeed - 7 Feb 2007
Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Jan 2007
Merck Serono Has Initiated the ONWARD Study to Evaluate Oral Cladribine as Add-on Treatment for Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 23 Jan 2007
Pharmion Submits European Marketing Authorization Application for Thalidomide Pharmion(R) for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Jan 2007
Sequella Receives FDA Fast Track Status for TB Drug
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Jan 2007
Cerus Announces French Regulatory Approval of the INTERCEPT Blood System for Plasma
Devices Regulatory

HSMN NewsFeed - 16 Jan 2007
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 Jan 2007
FDA Clears Humanetics' IND Filing to Commence Clinical Studies on New Radiation Countermeasure
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Jan 2007
CoGenesys Files to Begin Clinical Trials of Neugranin for the Prevention of Infections in Cancer Patients
Biopharmaceuticals

HSMN NewsFeed - 28 Dec 2006
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
Biopharmaceuticals

HSMN NewsFeed - 19 Dec 2006
GlaxoSmithKline and Genmab Enter Global Agreement For HuMax-CD20
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Dec 2006
American Cancer Society Journal Article Reports New Data Regarding Repeated Administration of QUADRAMET(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Dec 2006
Robert Brown Joins Biothera as Senior Vice President, Corporate Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Dec 2006
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Dec 2006
Abbott Introduces CE-Marked DNA Tests in Europe for the Detection of Chromosomal Abnormalities Associated With Leukemia
Diagnostics Oncology

HSMN NewsFeed - 1 Dec 2006
Pfizer Announces Plans to Establish Expanded Access Program for Maraviroc, Investigational HIV CCR5 Antagonist
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Nov 2006
Millennium Initiates Phase II Trial to Evaluate MLN3897 in Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 21 Nov 2006
Cerus Corporation Announces European Regulatory Approval for the INTERCEPT Blood System for Plasma
Devices Regulatory

HSMN NewsFeed - 31 Oct 2006
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Oct 2006
Detroit Receiving Offers Michigan's First Hospital-Based Hyperbaric Wound Care Program
Devices Wound Care

HSMN NewsFeed - 4 Oct 2006
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Sep 2006
Cerus Strengthens European Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Sep 2006
Neose Provides Update on GlycoPEG-GCSF Program
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Sep 2006
Serono's Oral Cladribine for the Treatment of Multiple Sclerosis Awarded Fast Track Status by FDA
Biopharmaceuticals FDA Neurology

HSMN NewsFeed - 18 Sep 2006
Combination of High Dose QUADRAMET(R) and Chemotherapy Shows Promise for Treatment of High-Risk Acute Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Jul 2006
Abbott Announces FDA Clearance of Cell-Dyn Ruby(TM) Hematology Instrument
Diagnostics FDA

HSMN NewsFeed - 19 Jul 2006
FDA Grants Intracel Special Protocol Assessment (SPA) for Confirmatory, Pivotal Phase III Study of OncoVAX(R) Colon Cancer Vaccine
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Jun 2006
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 May 2006
Thalomid(R) sNDA Granted FDA Approval For Treatment of Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 May 2006
Hana Biosciences Receives Orphan Drug Designation for Talotrexin (PT-523), For the Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 May 2006
Barr Receives Approval for Isotretinoin Capsules USP, 30 mg
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 8 May 2006
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
Biopharmaceuticals Oncology Licensing

Return to NewsFeed

Additional items found! 193

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 193 additional stories matching:
white blood cells
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!